Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218151 · ClinicalTrials.gov registry record · NA
Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02218151 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 61 participants.
The verdict
NCT02218151, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
Hematopoietic stem cell transplantation (HCT) has the potential to cure a variety of malignant and non-malignant diseases. However, it is associated with significant morbidity, and treatment-related mortality. This is due in large part to the prolonged pancytopenia and immunosuppression associated with the preparatory regimen of chemotherapy and/or radiation and the wait until engraftment of the transplanted hematopoietic stem cells. During this vulnerable period, infectious complications are common. Historically HCT patients were kept in protected environments to safeguard their health during the pancytopenic phase; despite these measures, infectious complications and graft versus host disease (GVHD) remained common and lead to significant morbidity and mortality after HCT. Currently patients are still closely watched in the inpatient or day hospital environment, though recent practices allow patients more freedom. This study randomizes eligible patients to receive post-transplant care at home vs. in the hospital or clinic, per standard of care. The primary objective is to compare the incidence of grade II-IV acute GVHD at 6 months in patients receiving patient-centered medical home (PCMH) vs standard care.
Interventions
- OTHER Standard Care
- OTHER Patient-Centered Medical Home (PCMH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-09-03 |
| Est. Completion | 2022-02-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218151
The ClinicalTrials.gov registry entry for NCT02218151 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT02218151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02218151 about?
NCT02218151 is a clinical study titled "Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2". Hematopoietic stem cell transplantation (HCT) has the potential to cure a variety of malignant and non-malignant diseases. However, it is associated with significant morbidity, and treatment-related mortality. This is due in large part to the prolonged pancytopenia and immunosuppression associated w...
What is the current status of trial NCT02218151?
This trial is currently terminated. It is a NA study. The enrollment target is 61 participants. The study started on 2014-09-03. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT02218151?
The interventions under investigation include: Standard Care (OTHER), Patient-Centered Medical Home (PCMH) (OTHER).
Who is sponsoring clinical trial NCT02218151?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.